{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:10:45Z","timestamp":1784740245235,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,7]]},"DOI":"10.7759\/cureus.68895","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T19:47:12Z","timestamp":1725738432000},"source":"Crossref","is-referenced-by-count":4,"title":["Comparative Analysis of Intravenous Immunoglobulins (IVIg) vs Plasmapheresis (PLEX) in the Management of Myasthenic Crisis"],"prefix":"10.7759","author":[{"given":"Ahmad","family":"Zain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shariq","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Ashfaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armghan","family":"Ans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasaan H","family":"Ans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders DB","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al.. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016, 87:419-25. 10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia ME","year":"2020","unstructured":"Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. Front Neurol. 2020, 11:604. 10.3389\/fneur.2020.00604","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1212\/01.CON.0000455873.30438.9b","article-title":"Myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"20","author":"Sanders DB","year":"2014","unstructured":"Sanders DB, Guptill JT. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum (Minneap Minn). 2014, 20:1413-25. 10.1212\/01.CON.0000455873.30438.9b","journal-title":"Continuum (Minneap Minn)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi A","year":"2007","unstructured":"Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci. 2007, 261:127-33. 10.1016\/j.jns.2007.04.045","journal-title":"J Neurol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50901","article-title":"Clinical outcome measures following plasma exchange for MG exacerbation","volume":"6","author":"Raja SM","year":"2019","unstructured":"Raja SM, Howard JF Jr, Juel VC, Massey JM, Chopra M, Guptill JT. Clinical outcome measures following plasma exchange for MG exacerbation. Ann Clin Transl Neurol. 2019, 6:2114-9. 10.1002\/acn3.50901","journal-title":"Ann Clin Transl Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb JP","year":"2014","unstructured":"Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014, 175:408-18. 10.1111\/cei.12217","journal-title":"Clin Exp Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile","volume":"102","author":"Dalakas MC","year":"2004","unstructured":"Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004, 102:177-93. 10.1016\/j.pharmthera.2004.04.002","journal-title":"Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas MC","year":"2004","unstructured":"Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004, 291:2367-75. 10.1001\/jama.291.19.2367","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas MC","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, et al.. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993, 329:1993-2000. 10.1056\/NEJM199312303292704","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s004150070149","article-title":"Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis","volume":"247","author":"Yeh JH","year":"2000","unstructured":"Yeh JH, Chiu HC. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol. 2000, 247:510-3. 10.1007\/s004150070149","journal-title":"J Neurol"},{"key":"ref11","article-title":"Plasmapheresis","author":"Sergent SR","year":"2024","unstructured":"Sergent SR, Ashurst JV. Plasmapheresis. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2024 Jan-."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0885066605276816","article-title":"Therapeutic apheresis in neurology critical care","volume":"20","author":"Natarajan N","year":"2005","unstructured":"Natarajan N, Weinstein R. Therapeutic apheresis in neurology critical care. J Intensive Care Med. 2005, 20:212-25. 10.1177\/0885066605276816","journal-title":"J Intensive Care Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1098-1101(2000)15:1\/2<74::aid-jca6>3.0.co;2-o","article-title":"Therapeutic apheresis in neurological disorders","volume":"15","author":"Weinstein R","year":"2000","unstructured":"Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apher. 2000, 15:74-128. 10.1002\/(sici)1098-1101(2000)15:1\/2&lt;74::aid-jca6&gt;3.0.co;2-o","journal-title":"J Clin Apher"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23508","article-title":"A retrospective study of complications of therapeutic plasma exchange in myasthenia","volume":"47","author":"Guptill JT","year":"2013","unstructured":"Guptill JT, Oakley D, Kuchibhatla M, et al.. A retrospective study of complications of therapeutic plasma exchange in myasthenia. Muscle Nerve. 2013, 47:170-6. 10.1002\/mus.23508","journal-title":"Muscle Nerve"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki A 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000, 55:16-23. 10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth D","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011, 76:2017-23. 10.1212\/WNL.0b013e31821e5505","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos P","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997, 41:789-96. 10.1002\/ana.410410615","journal-title":"Ann Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos P","year":"2003","unstructured":"Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2003, CD002277. 10.1002\/14651858.CD002277","journal-title":"Cochrane Database Syst Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus NE","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016, 375:2570-81. 10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi AI","year":"1999","unstructured":"Qureshi AI, Choudhry MA, Akbar MS, et al.. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999, 52:629-32. 10.1212\/wnl.52.3.629","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109058","article-title":"Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: a prospective cohort study","volume":"241","author":"Wang Y","year":"2022","unstructured":"Wang Y, Huan X, Jiao K, et al.. Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: a prospective cohort study. Clin Immunol. 2022, 241:109058. 10.1016\/j.clim.2022.109058","journal-title":"Clin Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1993.00540080046012","article-title":"Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin","volume":"50","author":"Stricker RB","year":"1993","unstructured":"Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol. 1993, 50:837-40. 10.1001\/archneur.1993.00540080046012","journal-title":"Arch Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.15050","article-title":"Myasthenic crisis: clinical features, complications and mortality","volume":"53","author":"Murthy JM","year":"2005","unstructured":"Murthy JM, Meena AK, Chowdary GV, Naryanan JT. Myasthenic crisis: clinical features, complications and mortality. Neurol India. 2005, 53:37-40; discussion 40. 10.4103\/0028-3886.15050","journal-title":"Neurol India"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123180","article-title":"Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: a systematic review and meta-analysis with special attention to faster relapse control","volume":"11","author":"Pavlekovics M","year":"2023","unstructured":"Pavlekovics M, Engh MA, Lugosi K, et al.. Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: a systematic review and meta-analysis with special attention to faster relapse control. Biomedicines. 2023, 11:10.3390\/biomedicines11123180","journal-title":"Biomedicines"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10095","article-title":"\"Crisis\" in myasthenia gravis: an historical perspective","volume":"26","author":"Keesey JC","year":"2002","unstructured":"Keesey JC. \"Crisis\" in myasthenia gravis: an historical perspective. Muscle Nerve. 2002, 26:1-3. 10.1002\/mus.10095","journal-title":"Muscle Nerve"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-999-0006-8","article-title":"Myasthenia gravis","volume":"1","author":"Lisak RP","year":"1999","unstructured":"Lisak RP. Myasthenia gravis. Curr Treat Options Neurol. 1999, 1:239-50. 10.1007\/s11940-999-0006-8","journal-title":"Curr Treat Options Neurol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-004-0025-4","article-title":"Myasthenia gravis","volume":"6","author":"Graves M","year":"2004","unstructured":"Graves M, Katz JS. Myasthenia gravis. Curr Treat Options Neurol. 2004, 6:163-71. 10.1007\/s11940-004-0025-4","journal-title":"Curr Treat Options Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e31822c34dd","article-title":"Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study","volume":"13","author":"Heatwole C","year":"2011","unstructured":"Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis. 2011, 13:85-94. 10.1097\/CND.0b013e31822c34dd","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24960","article-title":"Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis","volume":"53","author":"Furlan JC","year":"2016","unstructured":"Furlan JC, Barth D, Barnett C, Bril V. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Muscle Nerve. 2016, 53:872-6. 10.1002\/mus.24960","journal-title":"Muscle Nerve"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/188713-comparative-analysis-of-intravenous-immunoglobulins-ivig-vs-plasmapheresis-plex-in-the-management-of-myasthenic-crisis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T19:47:15Z","timestamp":1725738435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/188713-comparative-analysis-of-intravenous-immunoglobulins-ivig-vs-plasmapheresis-plex-in-the-management-of-myasthenic-crisis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.68895","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,7]]}}}